Lentiviral Mediating Genetic Engineered Mesenchymal Stem Cells for Releasing IL-27 as a Gene Therapy Approach for Autoimmune Diseases

Objective: autoimmune diseases precede a complex dysregulation of the immune system.t helper17 (th17) and interleukin (il)-17 have central roles in initiation of inflammationand subsequent autoimmune diseases. il-27 significantly controls autoimmunediseases by th17 and il-17 suppression. in the present study we have created geneticengineered mesenchymal stem cells (mscs) that mediate with lentiviral vectors to releaseil-27 as an adequate vehicle for ex vivo gene therapy in the reduction of inflammation andautoimmune diseases.materials and methods: in this experimental study, we isolated adipose-derived mscs(ad-mscs) from lipoaspirate and subsequently characterized them by differentiation. twosubunits of il-27 (p28 and ebi3) were cloned in a pcdh-513b-1 lentiviral vector. expressionsof p28 and ebi3 (epstein-barr virus induced gene 3) were determined by real timepolymerase chain reaction (pcr). mscs were transduced by a pcdh-cmv-p28-iresebi3-ef-copgfp-pur lentiviral vector and the bioassay of il-27 was evaluated by il-10expression.results: cell differentiation confirmed true isolation of mscs from lipoaspirate. restrictionenzyme digestion and sequencing verified successful cloning of both p28and ebi3 in the pcdh-513b-1 lentiviral vector. real time pcr showed high expressionslevel of il-27 and il-10 as well as accurate activity of il-27.conclusion: the results showed transduction of functional il-27 to ad-mscs by means of alentiviral vector. the lentiviral vector did not impact msc characteristics.